Biotech · Private company
ITM Solucin GmbH
Track this companyFree. Adds ITM Solucin GmbH to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRTPhase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- 177Lu-edotreotide PRRTPhase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Amino-Acid SolutionPhase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CAPTEM (Capecitabine and Temozolomide)Phase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- EverolimusPhase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)Phase 3 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Amino Acid SolutionPhase 1 · Somatostatin Receptor PositiveClinicalTrials.gov · fetched Nov 12, 2026
- Lutetium Lu 177-EdotreotidePhase 1 · Somatostatin Receptor PositiveClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsPHASE1 · RECRUITING · started Sep 26, 2025ClinicalTrials.gov NCT06441331 · fetched Nov 12, 2026
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 21, 2021ClinicalTrials.gov NCT04919226 · fetched Nov 12, 2026
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 2, 2017ClinicalTrials.gov NCT03049189 · fetched Nov 12, 2026